Trial · NCT03259308
Results by group144
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 144
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Remission Based on Composite Score at Week 12 | Placebo | 7 | Participants | ||
| Number of Participants With Remission Based on Composite Score at Week 12 | Ontamalimab 25 mg | 30 | Participants | ||
| Number of Participants With Remission Based on Composite Score at Week 12 | Ontamalimab 75 mg | 33 | Participants | ||
| Number of Participants With Endoscopic Remission at Week 12 | Placebo | 7 | Participants | ||
| Number of Participants With Endoscopic Remission at Week 12 | Ontamalimab 25 mg | 39 | Participants | ||
| Number of Participants With Endoscopic Remission at Week 12 | Ontamalimab 75 mg | 38 | Participants | ||
| Number of Participants With Clinical Remission at Week 12 | Placebo | 10 | Participants | ||
| Number of Participants With Clinical Remission at Week 12 | Ontamalimab 25 mg | 50 | Participants | ||
| Number of Participants With Clinical Remission at Week 12 | Ontamalimab 75 mg | 56 | Participants | ||
| Number of Participants With Clinical Response Based on Composite Score at Week 12 | Placebo | 16 | Participants | ||
| Number of Participants With Clinical Response Based on Composite Score at Week 12 | Ontamalimab 25 mg | 67 | Participants | ||
| Number of Participants With Clinical Response Based on Composite Score at Week 12 | Ontamalimab 75 mg | 64 | Participants | ||
| Number of Participants With Mucosal Healing Based on Endoscopic and Histological Assessment Using the Geboes Score Grading System at Week 12 | Placebo | 6 | Participants | ||
| Number of Participants With Mucosal Healing Based on Endoscopic and Histological Assessment Using the Geboes Score Grading System at Week 12 | Ontamalimab 25 mg | 35 | Participants | ||
| Number of Participants With Mucosal Healing Based on Endoscopic and Histological Assessment Using the Geboes Score Grading System at Week 12 | Ontamalimab 75 mg | 30 | Participants | ||
| Number of Participants With Remission Based on Total Mayo Score at Week 12 | Placebo | 5 | Participants | ||
| Number of Participants With Remission Based on Total Mayo Score at Week 12 | Ontamalimab 25 mg | 28 | Participants | ||
| Number of Participants With Remission Based on Total Mayo Score at Week 12 | Ontamalimab 75 mg | 26 | Participants | ||
| Number of Participants With Clinical Response Based on Total Mayo Score at Week 12 | Placebo | 19 | Participants | ||
| Number of Participants With Clinical Response Based on Total Mayo Score at Week 12 | Ontamalimab 25 mg | 66 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03259308/results